Search

Your search keyword '"Perrino, M."' showing total 18 results
Start Over Author "Perrino, M." Publisher elsevier bv
18 results on '"Perrino, M."'

1. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

Author

Proto, C., primary, Ganzinelli, M., additional, Manglaviti, S., additional, Imbimbo, M., additional, Galli, G., additional, Marabese, M., additional, Zollo, F., additional, Alvisi, M.F., additional, Perrino, M., additional, Cordua, N., additional, Borea, F., additional, de Vincenzo, F., additional, Chella, A., additional, Cappelli, S., additional, Pardini, E., additional, Ballatore, Z., additional, Lucarelli, A., additional, Ambrosini, E., additional, Giuliano, M., additional, Pietroluongo, E., additional, Mulargiu, C., additional, Fabbri, A., additional, Prelaj, A., additional, Occhipinti, M., additional, Brambilla, M., additional, Mazzeo, L., additional, Beninato, T., additional, Vigorito, R., additional, Ruggirello, M., additional, Greco, F.G., additional, Calareso, G., additional, Miliziano, D., additional, Rulli, E., additional, De Simone, I., additional, Torri, V., additional, de Braud, F.G.M., additional, Pasello, G., additional, De Placido, P., additional, Berardi, R., additional, Petrini, I., additional, Zucali, P., additional, Garassino, M.C., additional, and Lo Russo, G., additional

Published
2024
Full Text
View/download PDF

2. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Author

Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., Torri V., Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., and Torri V.

Abstract

Background: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum–pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are available in this population about durvalumab. Materials and methods: DIADEM was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab. Patients with locally advanced/metastatic MPM who progressed after platinum–pemetrexed chemotherapy were enrolled to receive durvalumab (1500 mg, intravenously Q4W) for 12 months or until evidence of disease progression or unacceptable toxicity. The primary endpoint was the proportion of patients alive and free from progression at 16 weeks (PFS16wks) calculated from treatment initiation. Secondary endpoints were progression-free survival, overall survival, overall response rate, and safety. Results: Sixty-nine patients with a median age of 69 years (range 44-82 years) were enrolled; 62 patients (89.9%) had epithelioid histotype. As first-line treatment, all patients received platinum derivatives–pemetrexed combination (60.9% with carboplatin and 39.1% with cisplatin). As of March 2021, the median follow-up was 9.2 months (interquartile range 5.2-11.1 months). Six patients (8.7%) completed the 12-month treatment; 60 patients discontinued, of whom 42 for progressive disease, and 4 died. Seventeen patients (28.3%; 95% confidence interval 17.5% to 41.4%) were alive or free from progression at 16 weeks. Eleven patients (18.6%) had a grade 3 or 4 treatment-related adverse event (AE), and one (1.4%) had a grade ≥3 immune-related, treatment-related AE. There was one drug-related death. Conclusion: Durvalumab alone in pretreated non-selected MPM did not reach a meaningful clinical activity, showing any new major safety issue signals.

Published
2022

3. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Author

Canova, S., primary, Ceresoli, G.L., additional, Grosso, F., additional, Zucali, P.A., additional, Gelsomino, F., additional, Pasello, G., additional, Mencoboni, M., additional, Rulli, E., additional, Galli, F., additional, De Simone, I., additional, Carlucci, L., additional, De Angelis, A., additional, Belletti, M., additional, Bonomi, M., additional, D’Aveni, A., additional, Perrino, M., additional, Bono, F., additional, Cortinovis, D.L., additional, Cortinovis, D., additional, Canova, S., additional, Colonese, F., additional, Abbate, M.I., additional, Sala, L., additional, Sala, E., additional, Perez Gila, M., additional, Pagni, F., additional, Ugo, F., additional, De Vincenzo, F., additional, Santoro, A., additional, Ardizzoni, A., additional, Frega, S., additional, D’Incalci, M., additional, Poli, D., additional, and Torri, V., additional

Published
2022
Full Text
View/download PDF

4. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)

Author

Proto, C., primary, Galli, G., additional, Manglaviti, S., additional, Lo Russo, G., additional, Ganzinelli, M., additional, Galli, F., additional, Musca, M., additional, Rulli, E., additional, Di Mauro, R., additional, Mella, G., additional, Lucarelli, A., additional, Paggio, A., additional, Valleggi, S., additional, Ballatore, Z., additional, Maso, A. Dal, additional, Perrino, M., additional, Chella, A., additional, Sbrana, A., additional, Prelaj, A., additional, Ferrara, R., additional, Occhipinti, M., additional, Brambilla, M., additional, De Toma, A., additional, Mazzeo, L., additional, Beninato, T., additional, Pircher, C., additional, de Braud, F., additional, Pasello, G., additional, Petrini, I., additional, Berardi, R., additional, Garassino, M., additional, and Zucali, P., additional

Published
2022
Full Text
View/download PDF

5. The switching phenotype and intratumor plasticity in carcinoma of the bladder: A mono-institutional analysis of 211 muscle-invasive carcinoma patients with clinical considerations for therapy

Author

Colombo, P., primary, Zucali, P.A., additional, De Carlo, C., additional, Elefante, G.M., additional, Hurle, R., additional, Lazzeri, M., additional, D’Antonio, F., additional, Cieri, M., additional, Giordano, L., additional, Perrino, M., additional, Belsito, V., additional, Santoro, A., additional, Guazzoni, G., additional, and Terracciano, L.M., additional

Published
2021
Full Text
View/download PDF

6. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Author

Metaxas, Y., primary, Früh, M., additional, Eboulet, E.I., additional, Grosso, F., additional, Pless, M., additional, Zucali, P.A., additional, Ceresoli, G.L., additional, Mark, M., additional, Schneider, M., additional, Maconi, A., additional, Perrino, M., additional, Biaggi-Rudolf, C., additional, Froesch, P., additional, Schmid, S., additional, Waibel, C., additional, Appenzeller, C., additional, Rauch, D., additional, and von Moos, R., additional

Published
2020
Full Text
View/download PDF

7. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

Author

Giovannetti, E., primary, Zucali, P.A., additional, Assaraf, Y.G., additional, Funel, N., additional, Gemelli, M., additional, Stark, M., additional, Thunnissen, E., additional, Hou, Z., additional, Muller, I.B., additional, Struys, E.A., additional, Perrino, M., additional, Jansen, G., additional, Matherly, L.H., additional, and Peters, G.J., additional

Published
2017
Full Text
View/download PDF

9. Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial

Author

Lopci, E., primary, Zucali, P., additional, Ceresoli, G., additional, Testori, A., additional, Voulaz, E., additional, Marzo, K., additional, Leonardi, L., additional, Rodari, M., additional, Olivari, L., additional, Ferraroli, G., additional, Bottoni, E., additional, Perrino, M., additional, Crepaldi, A., additional, Galeassi, A., additional, Gurrieri, L., additional, Veronesi, G., additional, Alloisio, M., additional, Santoro, A., additional, and Chiti, A., additional

Published
2016
Full Text
View/download PDF

10. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients

Author

Ceresoli, G.L., primary, Zucali, P.A., additional, Grosso, F., additional, Mencoboni, M., additional, Sauta, M.G., additional, Soto Parra, H.J., additional, Pasello, G., additional, Cortinovis, D., additional, Perrino, M., additional, Muzio, A., additional, Bruzzone, A., additional, De Vincenzo, F., additional, Degiovanni, D., additional, Bonomi, M., additional, Simonelli, M., additional, Beretta, G.D., additional, Giordano, L., additional, and Santoro, A., additional

Published
2015
Full Text
View/download PDF

11. Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial

Author

Zucali, P.A., primary, Simonelli, M., additional, De Vincenzo, F., additional, Fatuzzo, G., additional, Bertossi, M., additional, Perrino, M., additional, Miggiano, C., additional, Giordano, L., additional, Bonifacio, C., additional, Mrakic Sposta, F., additional, and Santoro, A., additional

Published
2015
Full Text
View/download PDF

16. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Author

Zucali, P.A., primary, Simonelli, M., additional, Michetti, G., additional, Tiseo, M., additional, Ceresoli, G.L., additional, Collovà, E., additional, Follador, A., additional, Lo Dico, M., additional, Moretti, A., additional, De Vincenzo, F., additional, Lorenzi, E., additional, Perrino, M., additional, Giordano, L., additional, Farina, G., additional, Santoro, A., additional, and Garassino, M., additional

Published
2012
Full Text
View/download PDF

17. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Author

Fabio Conforti, Paolo Andrea Zucali, Laura Pala, Chiara Catania, Vincenzo Bagnardi, Isabella Sala, Paolo Della Vigna, Matteo Perrino, Paola Zagami, Chiara Corti, Sara Stucchi, Massimo Barberis, Elena Guerini-Rocco, Benedetta Di Venosa, Fabio De Vincenzo, Nadia Cordua, Armando Santoro, Giuseppe Giaccone, Tommaso Martino De Pas, Conforti, F, Zucali, P, Pala, L, Catania, C, Bagnardi, V, Sala, I, Della Vigna, P, Perrino, M, Zagami, P, Corti, C, Stucchi, S, Barberis, M, Guerini-Rocco, E, Di Venosa, B, De Vincenzo, F, Cordua, N, Santoro, A, Giaccone, G, and Martino De Pas, T

Subjects
Adolescent, Axitinib, Thymoma, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Angiogenesis Inhibitors, Thymus Neoplasms, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Polymyositis
Abstract

Background: Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy have few treatment options. We report the efficacy and safety results of the combination of the anti-PD-L1 inhibitor avelumab with the anti-angiogenesis drug axitinib in patients with advanced type B3 thymoma and thymic carcinoma. Methods: CAVEATT was a single-arm, multicentre, phase 2 trial, conducted in two Italian centres (the European Instituteof Oncology and the Humanitas Institute, Milan) in patients with histologically confirmed type B3 thymoma or thymic carcinoma, with advanced stage of disease who had progressed after at least one line of platinum-based chemotherapy. Previous treatment with an anti-angiogenesis drug was allowed but not with immune checkpoint inhibitors. Other inclusion criteria were age 18 years or older, an Eastern Cooperative Oncology Group performance status of 0–2, progressive disease, and presence of measurable disease according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Patients received avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily until disease progression or unacceptable toxicity. The primary endpoint was the centrally assessed overall response rate according to RECIST version 1.1. Patients who received at least one cycle of treatment and had at least one CT scan after treatment start at scheduled time point by protocol were judged assessable for response and were included in efficacy and safety analyses. This study is registered with EUDRACT, 2017–004048–38; enrolment is completed and follow-up is ongoing. Findings: Between April 22, 2019, and June 30, 2021, 32 patients were enrolled. 27 patients had a thymic carcinoma, three a type B3 thymoma, and two a mixed type B3 thymoma and thymic carcinoma. 29 (91%) of 32 patients had stage IVB disease and 13 (41%) of 32 had been pretreated with an anti-angiogenesis drug. 11 of 32 patients had an overall response; thus the overall response rate was 34% (90% CI 21–50); no patients had a complete response, 11 (34%) had a partial response, 18 (56%) had stable disease, and in two patients (6%) progressive disease was the best response. The most common grade 3 or 4 adverse event was hypertension (grade 3 in six [19%] of 32 patients). Four (12%) of 32 patients developed serious adverse events that were new-onset immune-related adverse events, including one grade 3 interstitial pneumonitis, one grade 4 polymyositis, and two grade 3 polymyositis. There were no treatment-related deaths. Interpretation: Avelumab combined with axitinib has promising anti-tumour activity and acceptable toxicity in patients with advanced type B3 thymoma and thymic carcinoma progressing after chemotherapy, and could emerge as a new standard treatment option in this setting. Funding: Pfizer.

Published
2022
Full Text
View/download PDF

18. Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial

Author

Lorenzo Leonardi, Marco Alloisio, Alessandro Crepaldi, Arturo Chiti, Giovanni Luca Ceresoli, Armando Santoro, Egesta Lopci, Katia Marzo, Giulia Veronesi, Paolo Andrea Zucali, Edoardo Bottoni, A. Galeassi, Matteo Perrino, Alberto Testori, Giorgio Maria Ferraroli, Laura Olivari, Marcello Rodari, L. Gurrieri, Emanuele Voulaz, Lopci, E., Zucali, P., Ceresoli, G., Testori, A., Voulaz, E., Marzo, K., Leonardi, L., Rodari, M., Olivari, L., Ferraroli, G., Bottoni, E., Perrino, M., Crepaldi, A., Galeassi, A., Gurrieri, L., Veronesi, G., Alloisio, M., Santoro, A., and Chiti, A.

Subjects
medicine.medical_specialty, 11c methionine pet, business.industry, Talc pleurodesis, Hematology, medicine.disease, Surgery, Clinical trial, Oncology, Interim, medicine, Malignant pleural effusion, Radiology, business
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results